From Brisbane to China: Supporting global drug development  

Resolian is a global Contract Research Organisation (CRO) providing critical laboratory services to pharmaceutical and biotechnology companies developing innovative therapies worldwide. 

Resolian’s Brisbane laboratory plays an important role within the organisation’s expanding global network, which spans the United States, the United Kingdom and China.  

The company’s Brisbane team specialises in high‑quality bioanalytical testing, supporting every stage of new drug development from early discovery through to clinical trials. This expertise positions Queensland at the forefront of global life sciences and biomedical innovation. 

A growing number of Resolian’s programs involve Chinese biotechnology companies or clinical trials with sites in China. This reflects the rapid growth of China’s biotech sector and its increasing significance in the global pharmaceutical landscape. As international collaboration becomes ever more critical to bringing new therapies to market, Resolian’s global footprint enables seamless delivery across borders, time zones and regulatory environments. 

Trade and Investment Queensland (TIQ) has supported Resolian’s Brisbane laboratory by facilitating connections with key partners in China and helping to showcase Queensland’s world‑class scientific capability on the global stage. Through trade engagement and market insight, TIQ has helped strengthen pathways for collaboration and growth, reinforcing Queensland’s reputation as a trusted destination for advanced life sciences research. 

By combining local expertise with global reach, Resolian’s Brisbane laboratory continues to support the development of life‑changing medicines while contributing to Queensland’s growing profile as an internationally connected life sciences hub. As demand for innovative therapies continues to rise worldwide, Resolian and Queensland’s research ecosystem are well placed to support the future of global drug development.